(Website under construction)                                      HOME       ABOUT      PIPELINE        
 
  

 PRESS RELEASE


(September 15, 2015) – Daiichi Sankyo Company, Ltd. today announced that it has signed an exclusive licensing agreement with Translational Sciences, Inc. to develop and commercialize its novel thrombus (blood clot) dissolving agent, TS23.

 

This agreement with Translational Sciences, Inc. for Daiichi Sankyo to develop and commercialize this unique thrombus dissolving agent, TS23, is in line with the Daiichi Sankyo R&D strategy to expand its portfolio in the prevention and treatment of thrombosis.

 

Dr. Guy Reed, CSO/CEO of Translational Sciences said: “Daiichi Sankyo recognized the great potential of this novel therapy. We believe they have the expertise and resources to fully develop it for the millions of patients each year who suffer cardiovascular disease and stroke. We are enormously grateful to the National Institutes of Health who provided crucial support to translate this research into therapy.  


  

    

Translational Sciences, Inc. is a clinical stage, biopharmaceutical company that develops first-in-class therapeutics for safe and effective treatment of acute thrombotic cardiovascular diseases and ischemic stroke.

 

___________________________________________________


Translational Sciences, Inc. is a clinical stage, biopharmaceutical company that develops first-in-class therapeutics for the safe and effective treatment of acute cardiovascular diseases and ischemic stroke. Reasearch is supported by the National Institutes of Health, specifically the National Heart, Lung, And Blood Institute (Award R44HL092750) and the National Institute Of Neurological Disorders And Stroke (Award U44NS073147).